190 related articles for article (PubMed ID: 38702996)
21. Not All Immune Checkpoints Are Created Equal.
De Sousa Linhares A; Leitner J; Grabmeier-Pfistershammer K; Steinberger P
Front Immunol; 2018; 9():1909. PubMed ID: 30233564
[TBL] [Abstract][Full Text] [Related]
22. Lag-3 expression and clinical outcomes in metastatic melanoma patients treated with combination anti-lag-3 + anti-PD-1-based immunotherapies.
Gide TN; Paver EC; Yaseen Z; Maher N; Adegoke N; Menzies AM; Pires da Silva I; Wilmott JS; Long GV; Scolyer RA
Oncoimmunology; 2023; 12(1):2261248. PubMed ID: 37808404
[TBL] [Abstract][Full Text] [Related]
23. Systemic treatments for metastatic cutaneous melanoma.
Pasquali S; Hadjinicolaou AV; Chiarion Sileni V; Rossi CR; Mocellin S
Cochrane Database Syst Rev; 2018 Feb; 2(2):CD011123. PubMed ID: 29405038
[TBL] [Abstract][Full Text] [Related]
24. LAG-3 transcriptomic expression correlates linearly with other checkpoints, but not with clinical outcomes.
Adashek JJ; Kato S; Nishizaki D; Pabla S; Nesline MK; Previs RA; Conroy JM; DePietro P; Kurzrock R
Am J Cancer Res; 2024; 14(1):368-377. PubMed ID: 38323282
[TBL] [Abstract][Full Text] [Related]
25. Strategies to Improve the Antitumor Effect of Immunotherapy for Hepatocellular Carcinoma.
Xing R; Gao J; Cui Q; Wang Q
Front Immunol; 2021; 12():783236. PubMed ID: 34899747
[TBL] [Abstract][Full Text] [Related]
26. Comprehensive immunophenotyping of solid tumor-infiltrating immune cells reveals the expression characteristics of LAG-3 and its ligands.
Garman B; Jiang C; Daouti S; Kumar S; Mehta P; Jacques MK; Menard L; Manjarrez-Orduno N; Dolfi S; Mukherjee P; Rai SC; Lako A; Koenitzer JD; David JM
Front Immunol; 2023; 14():1151748. PubMed ID: 37795090
[TBL] [Abstract][Full Text] [Related]
27. Metabolic interventions combined with CTLA-4 and PD-1/PD-L1 blockade for the treatment of tumors: mechanisms and strategies.
Liao L; Xu H; Zhao Y; Zheng X
Front Med; 2023 Oct; 17(5):805-822. PubMed ID: 37897562
[TBL] [Abstract][Full Text] [Related]
28. Intratumoral Immunotherapy-Update 2019.
Hamid O; Ismail R; Puzanov I
Oncologist; 2020 Mar; 25(3):e423-e438. PubMed ID: 32162802
[TBL] [Abstract][Full Text] [Related]
29. Emerging immune checkpoints in the tumor microenvironment: Implications for cancer immunotherapy.
Wei G; Zhang H; Zhao H; Wang J; Wu N; Li L; Wu J; Zhang D
Cancer Lett; 2021 Jul; 511():68-76. PubMed ID: 33957184
[TBL] [Abstract][Full Text] [Related]
30. New Clinical Approaches and Emerging Evidence on Immune-Checkpoint Inhibitors as Anti-Cancer Therapeutics: CTLA-4 and PD-1 Pathways and Beyond.
Christodoulou MI; Zaravinos A
Crit Rev Immunol; 2019; 39(5):379-408. PubMed ID: 32422018
[TBL] [Abstract][Full Text] [Related]
31. Combinational immunotherapy based on immune checkpoints inhibitors in small cell lung cancer: is this the beginning to reverse the refractory situation?
Guo H; He Y; Chen P; Wang L; Li W; Chen B; Liu Y; Wang H; Zhao S; Zhou C
J Thorac Dis; 2020 Oct; 12(10):6070-6089. PubMed ID: 33209440
[TBL] [Abstract][Full Text] [Related]
32. Treatment of advanced hepatocellular carcinoma: immunotherapy from checkpoint blockade to potential of cellular treatment.
Siu EH; Chan AW; Chong CC; Chan SL; Lo KW; Cheung ST
Transl Gastroenterol Hepatol; 2018; 3():89. PubMed ID: 30603725
[TBL] [Abstract][Full Text] [Related]
33. Novel Immunotherapy Combinations.
Bashir B; Wilson MA
Curr Oncol Rep; 2019 Nov; 21(11):96. PubMed ID: 31696332
[TBL] [Abstract][Full Text] [Related]
34. Anti-PD-1 and Anti-CTLA-4 Therapies in Cancer: Mechanisms of Action, Efficacy, and Limitations.
Seidel JA; Otsuka A; Kabashima K
Front Oncol; 2018; 8():86. PubMed ID: 29644214
[TBL] [Abstract][Full Text] [Related]
35. Clinical Insights Into Novel Immune Checkpoint Inhibitors.
Lee JB; Ha SJ; Kim HR
Front Pharmacol; 2021; 12():681320. PubMed ID: 34025438
[TBL] [Abstract][Full Text] [Related]
36. A Systematic Review of the Emerging Role of Immune Checkpoint Inhibitors in Metastatic Castration-resistant Prostate Cancer: Will Combination Strategies Improve Efficacy?
Heidegger I; Necchi A; Pircher A; Tsaur I; Marra G; Kasivisvanathan V; Kretschmer A; Mathieu R; Ceci F; van den Bergh RCN; Thibault C; Tilki D; Valerio M; Surcel C; Gandaglia G;
Eur Urol Oncol; 2021 Oct; 4(5):745-754. PubMed ID: 33243663
[TBL] [Abstract][Full Text] [Related]
37. Immune Checkpoint Inhibitors in Peripheral T-Cell Lymphoma.
Chen X; Wu W; Wei W; Zou L
Front Pharmacol; 2022; 13():869488. PubMed ID: 35559250
[TBL] [Abstract][Full Text] [Related]
38. PD-1/LAG-3 bispecific antibody potentiates T cell activation and increases antitumor efficacy.
Shi N; Zhou Y; Liu Y; Zhang R; Jiang X; Ren C; Gao X; Luo L
Front Immunol; 2022; 13():1047610. PubMed ID: 36518768
[TBL] [Abstract][Full Text] [Related]
39. Understanding and overcoming resistance to immunotherapy in genitourinary cancers.
Evans ST; Jani Y; Jansen CS; Yildirim A; Kalemoglu E; Bilen MA
Cancer Biol Ther; 2024 Dec; 25(1):2342599. PubMed ID: 38629578
[TBL] [Abstract][Full Text] [Related]
40. Resistance to Checkpoint Inhibition in Cancer Immunotherapy.
Barrueto L; Caminero F; Cash L; Makris C; Lamichhane P; Deshmukh RR
Transl Oncol; 2020 Mar; 13(3):100738. PubMed ID: 32114384
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]